Summary
Health Canada authorized Nemluvio®, a first-in-class biologic for eczema and prurigo nodularis that specifically targets the biological cause of chronic itch. While national funding reviews are still underway, this approval provides a vital new option for patients who haven't found relief with standard creams.
A new era in dermatological care has arrived for Canadians suffering from chronic, debilitating itch. Health Canada authorized Nemluvio® (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis (eczema) in patients aged 12 and older, as well as prurigo nodularis in adults.
Nemluvio® is a first-in-class biologic that specifically targets the neuro-immune pathway responsible for itch, providing a much-needed alternative for patients whose conditions are not adequately controlled by topical therapies.
Targeting the “Itch Cytokine”
Unlike traditional eczema treatments that focus primarily on skin inflammation, Nemluvio® is the first monoclonal antibody designed to block interleukin-31 (IL-31). Often referred to by scientists as the “itch cytokine,” IL-31 sends signals directly to the nervous system to trigger the urge to scratch.
By blocking this signal, Nemluvio® addresses the most burdensome symptom of these conditions: the relentless itch that leads to sleep deprivation, skin damage, and significant mental health strain.
“Nemolizumab’s ability to rapidly target itch makes it an exciting and much-needed advancement, offering patients relief where they need it most,” said Dr. Chih-ho Hong, Board-Certified Dermatologist, MD, FRCPC, Surrey, BC.
Proven Clinical Success
The Health Canada authorization was based on robust data from two major Phase III clinical programs:
- ARCADIA 1 & 2 (Atopic Dermatitis): These trials demonstrated that Nemluvio, administered every four weeks, significantly improved skin lesions and reduced itch in adults and adolescents.
- OLYMPIA 1 & 2 (Prurigo Nodularis): This program, the largest of its kind for this condition, showed that the treatment significantly improved itch and cleared skin nodules compared to a placebo.
Status in Canada: The Road to Access
While Nemluvio® is now authorized for sale in Canada, its widespread availability under public insurance is still in progress.
- Reimbursement Review: The drug is currently undergoing a cost-effectiveness review by Canada’s Drug Agency (CDA-AMC). This national review is a required step before the drug can be listed on federal, provincial, and territorial public drug plans.
- Cost & Funding: Because the review is ongoing, an official, widely available list price for patient use has not yet been finalized or publicly released. Until funding decisions are made by the provinces, Nemluvio® is not yet a regular benefit under most public insurance plans.
- Patient Support: Historically, specialty biologics are supported by manufacturer-led patient assistance programs. These programs often help patients navigate early access and insurance coverage during the reimbursement review phase.
Is It Right For You?
Nemluvio® is intended for those whose disease is not adequately controlled with topical prescription therapies. Because it is an injectable medication given once every four weeks, it offers a convenient schedule for those looking to move away from daily creams or more frequent injections.
Subscribe to The Health Insider newsletter for more evidence-based updates on Canadian medical breakthroughs.
~ Read more from The Health Insider ~
- Health Canada Authorizes Nemluvio® for Eczema and Prurigo Nodularis
Health Canada authorized Nemluvio® (nemolizumab), a first-in-class biologic for eczema and prurigo nodularis. Learn about costs and coverage. - Health Canada Authorizes First GLP-1 Pill to Reduce Heart Attack and Stroke RiskHealth Canada authorizes RYBELSUS® as the first oral GLP-1 to reduce heart attack and stroke risk in adults with type 2 diabetes.
- Confronting the Silence Around Dementia: Why Not Knowing Isn’t a StrategyNew data reveals Canadians are avoiding dementia diagnoses and how facing the facts early can preserve your independence and health.
- The Mood Menu: How Your Plate Shapes Your MindDiscover how simple food choices like turkey and yogurt can boost your serotonin and stabilize your mood.
- Health Canada Authorizes First 8-Week Treatment for Acute Hepatitis CHealth Canada’s approval of MAVIRET for acute HCV allows doctors to treat adults and children immediately, a key step toward the 2030 elimination goal.
- The 7-Day Reset: A Social Media Break Can Transform Your Mental HealthDiscover why science says you only need one week off social media to lower anxiety and sleep better. A practical guide for the modern Canadian.
The information provided on TheHealthInsider.ca is for educational purposes only and does not substitute for professional medical advice. TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment. To read about our editorial review process click here.
